Document
IPR2017-00190, No. 1508-156 Exhibit - Deposition Transcript of Dr Boni E Elewski (P.T.A.B. Nov. 1, 2017)
Cite Document
IPR2017-00190, No. 1508-156 Exhibit - Deposition Transcript of Dr Boni E Elewski (P.T.A.B. Nov. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 2022-68 Exhibit - Kaken Exhibit 2022 (P.T.A.B. Feb. 2, 2017)
Cite Document
IPR2017-00190, No. 2022-68 Exhibit - Kaken Exhibit 2022 (P.T.A.B. Feb. 2, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1657-306 Exhibit - Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations Search results for Terbinafine (P.T.A.B. Nov. 1, 2017)
Cite Document
IPR2017-00190, No. 1657-306 Exhibit - Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations Search results for Terbinafine (P.T.A.B. Nov. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1580-229 Exhibit - Inside the Secret World of Drug Company Rebates (P.T.A.B. Nov. 1, 2017)
Cite Document
IPR2017-00190, No. 1580-229 Exhibit - Inside the Secret World of Drug Company Rebates (P.T.A.B. Nov. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 2004-50 Exhibit - Kaken Exhibit 2004 (P.T.A.B. Feb. 2, 2017)
Cite Document
IPR2017-00190, No. 2004-50 Exhibit - Kaken Exhibit 2004 (P.T.A.B. Feb. 2, 2017)
+ More Snippets
Document
IPR2017-00190, No. 2021-67 Exhibit - Kaken Exhibit 2021 (P.T.A.B. Feb. 2, 2017)
Cite Document
IPR2017-00190, No. 2021-67 Exhibit - Kaken Exhibit 2021 (P.T.A.B. Feb. 2, 2017)
+ More Snippets
Document
IPR2017-00190, No. 2090-136 Exhibit - Kaken Exhibit 2090 (P.T.A.B. Aug. 1, 2017)
Cite Document
IPR2017-00190, No. 2090-136 Exhibit - Kaken Exhibit 2090 (P.T.A.B. Aug. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1626-275 Exhibit - Copay Programs¿¿¿ Increased Value to Manufacturers is Matched by Rising Criticism,¿¿¿ S Shelly, Pharmaceutical Commerce, January 15, 2014 (P.T.A.B. ...
Cite Document
IPR2017-00190, No. 1626-275 Exhibit - Copay Programs¿¿¿ Increased Value to Manufacturers is Matched by Rising Criticism,¿¿¿ S Shelly, Pharmaceutical Commerce, January 15, 2014 (P.T.A.B. Nov. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1647-296 Exhibit - Consolidated Financial Results for Fiscal 2015 (P.T.A.B. Nov. 1, 2017)
Cite Document
IPR2017-00190, No. 1647-296 Exhibit - Consolidated Financial Results for Fiscal 2015 (P.T.A.B. Nov. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1029-29 Exhibit - Hay, RJ, Journal of Antimicrobial Chemotherapy 20 1 5 1987 (P.T.A.B. Nov. 2, 2016)
Cite Document
IPR2017-00190, No. 1029-29 Exhibit - Hay, RJ, Journal of Antimicrobial Chemotherapy 20 1 5 1987 (P.T.A.B. Nov. 2, 2016)
+ More Snippets
Document
IPR2017-00190, No. 2032-79 Exhibit - Kaken Exhibit 2032 (P.T.A.B. Aug. 1, 2017)
Cite Document
IPR2017-00190, No. 2032-79 Exhibit - Kaken Exhibit 2032 (P.T.A.B. Aug. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 2049-96 Exhibit - Kaken Exhibit 2049 (P.T.A.B. Aug. 1, 2017)
Cite Document
IPR2017-00190, No. 2049-96 Exhibit - Kaken Exhibit 2049 (P.T.A.B. Aug. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1624-273 Exhibit - Physician Awareness of Drug Cost A Systematic Review (P.T.A.B. Nov. 1, 2017)
Cite Document
IPR2017-00190, No. 1624-273 Exhibit - Physician Awareness of Drug Cost A Systematic Review (P.T.A.B. Nov. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1530-179 Exhibit - Valeant, Philidor RX, and the Uninformed Attack on Specialty Pharmacy (P.T.A.B. Nov. 1, 2017)
Cite Document
IPR2017-00190, No. 1530-179 Exhibit - Valeant, Philidor RX, and the Uninformed Attack on Specialty Pharmacy (P.T.A.B. Nov. 1, 2017)
+ More Snippets
Document
IPR2017-00190, No. 1518-167 Exhibit - Risk factors and comorbidities for onychomycosis implications for treatment with topical therapy (P.T.A.B. Nov. 1, 2017)
Cite Document
IPR2017-00190, No. 1518-167 Exhibit - Risk factors and comorbidities for onychomycosis implications for treatment with topical therapy (P.T.A.B. Nov. 1, 2017)
+ More Snippets